ACTRIMS Forum 2020

The 2020 ACTRIMS Forum offers an excellent opportunity to interact with over 1200 scientists and clinicians at the cutting edge of MS research, and stands apart from many traditional medical meetings by offering a singular track of scientific and clinical presentations in an interactive environment, as well as numerous networking opportunities. It takes place February 27-29, 2020, in West Palm Beach, Florida.
In episode 11, Clyde Markowitz, MD, provides an expert perspective on other exciting data in the field of multiple sclerosis management that were presented at the ACTRIMS 2020 meeting.
In episode 10, Clyde Markowitz, MD, reflects on the importance of a standardized MRI protocol in light of the ACTRIMS 2020 meeting.
In episode 9, Patricia Coyle, MD, discusses recent updates to the standardized MRI imaging protocol for the brain and spinal cord in multiple sclerosis and noteworthy findings from the ACTRIMS Forum 2020.
The director of Pediatric MS and Wellness programming at the Mellen Center and assistant professor of neurology at Cleveland Clinic Lerner College of Medicine discussed the harsh realities of patients adopting a new treatment method.
In episode 8, Clyde Markowitz, MD, details the considerations for B-cell depletion in the APLIOS bioequivalence study, presented at the ACTRIMS 2020 meeting.
In episode 7, Patricia Coyle MD, discusses the phase 2 APLIOS bioequivalence study on B-cell depletion with the subcutaneous administration of ofatumumab in relapsing multiple sclerosis.
The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health detailed what can currently be surmised about siponimod’s effect in treating patients with SPMS.
In episode 6, Clyde E. Markowitz, MD, gives a review of data from the ACTRIMS 2020 meeting in light of 6-year follow-up data with ocrelizumab therapy.
In episode 5, Patricia Coyle, MD details the six-year data from the phase 3 OPERA I/II studies on the use of ocrelizumab and the impact on confirmed disability progression in patients with multiple sclerosis.
The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed the findings of a subanalysis of the EXPAND study of siponimod in patients with secondary progressive multiple sclerosis.
In episode 4, Clyde Markowitz, MD, discusses ACTRIMS 2020 meeting data regarding the effect of disease duration on efficacy and safety of siponimod.
The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed the need to take age into consideration when managing a patient with MS, and how the thinking about the disease and age has shifted.
The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health detailed the current thinking about the challenges of addressing multiple sclerosis in older patients.
The chief medical officer of Clene Nanomedicine detailed CNM-Au8, their novel investigational drug currently being assessed in multiple trials for patients with multiple sclerosis and other neurodegenerative diseases.
In episode 3, Patricia K. Coyle, MD, gives a review of the phase 3 EXPAND trial in secondary progressive MS and the real-world significance of the data.
In episode 2, Clyde Markowitz, MD discusses cladribine data from the ACTRIMS 2020 meeting, regarding both reduction of risk of SPMS and time to first relapse after treatment. 
In episode 1, Patricia K. Coyle, MD, provides insight on data released at the ACTRIMS Forum 2020 on the phase 3 CLARITY trial assessing the benefit of oral cladribine for relapsing multiple sclerosis.
The director of Pediatric MS and Wellness at the Mellen Center and assistant professor of neurology at Cleveland Clinic Lerner College of Medicine describes her study on shared medical appointments and the intricacies of integrating them into the common care realm.
The assistant professor of neurology at the Lerner College of Medicine and neurologist at Luo Ruvo Center for Brain Health, both of Cleveland Clinic, discussed the challenges of current measurements and the need to adjust the reading of progressive MS.
The director of the Partners Pediatric MS Center at Massachusetts General Hospital for Children provided insight on the consequences of incomplete relapse recovery in multiple sclerosis.
The assistant professor of neurology at the Lerner College of Medicine and neurologist at Luo Ruvo Center for Brain Health, both of Cleveland Clinic, spoke to the importance of preventing progression in MS and treating the non-inflammatory aspects of the disease.
The associate professor in the department of neurology at the University of Colorado and neurologist at Advanced Neurology of Colorado discussed the advantages of cladribine and details of the ongoing CLICK-MS study.